Kamada Ltd. (KMDA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 4.5500 |
| Open | 4.5300 |
| Bid | 4.4000 x 1000 |
| Ask | 5.3800 x 1000 |
| Day's Range | 4.5000 - 4.5300 |
| 52 Week Range | 4.4200 - 6.9600 |
| Volume | |
| Avg. Volume | 17,255 |
| Market Cap | 201.602M |
| Beta (5Y Monthly) | 0.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1500 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for KMDA
Related Research
- Kamada Ltd.Analyst Report: Incyte Corp.Founded in 1991 and based in Wilmington, Delaware, Incyte is a drug discovery and development company. The company has several small-molecule compounds in clinical trials, while its primary revenue-generating products include Jakafi, Iclusig, Pemazyre, and Olumiant. Jakafi treats polycythemia vera (PV), a type of blood cancer; myelofibrosis (MF), a rare bone marrow disorder; and steroid-refractory acute graft-versus-host-disease (GVHD), while Iclusig treats leukemia, Pemazyre treats bile duct cancer, and Olumiant treats rheumatoid arthritis. The company also recently launched Tabrecta, for non-small-cell lung cancer, and has several active Phase 2 and 3 programs in oncology.RatingFair ValueEconomic Moat2 days agoArgus Research
- Zacks
Kamada (KMDA) Reports Q1 Loss, Lags Revenue Estimates
Kamada (KMDA) delivered earnings and revenue surprises of -233.33% and 13.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Kamada Reports First Quarter 2022 Financial Results; Reiterates Revenue and Profitability Guidance with Significant Growth Expected in 2022
First Quarter 2022 Revenues were $28.1 Million, Up 13% Year Over Year.Kamada Reiterates Fiscal Year 2022 Revenue Guidance of $125 - $135 Million, Representing a 20% to 30% Increase over 2021 and EBITDA Margins Anticipated Between 12%-15%, More Than 2.5X over 2021 EBITDA.Revenues and Profitability Margins of Recently Acquired Portfolio of Four FDA-Approved Commercial Products Within Management Expectations; Expanding Sales in Additional New Countries, Mainly in the Middle East Region.GLASSIA® Roy
- GlobeNewswire
Kamada Announces Expansion of Pivotal Phase 3 Clinical Trial of Inhaled AAT to Additional Six Clinical Sites Across Europe; and Positive Recommendation by DSMB to Continue the Trial Without Modification
REHOVOT, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today provided an update on recent progress achieved in its ongoing pivotal Phase 3 InnovAATe clinical trial evaluating the safety and efficacy of the Company’s proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). Following the recent mod
